Magnesium Trial in Acute Asthma in Emergency Department

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Asthma
Interventions
DRUG

magnesium sulfate

After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]

DRUG

Normal Saline

After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].

Trial Locations (6)

T3B 6A8

Alberta Children's Hospital, Calgary

T6G 2B7

Stollery Children's Hospital, Edmonton

L8S 4L8

McMaster Children's Hospital, Hamilton

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

M5G 1X8

The Hospital for Sick Children, Toronto

H3T 1C5

CHU-Sainte Justine Hospital, Montreal

All Listed Sponsors
collaborator

Alberta Children's Hospital

OTHER

collaborator

McMaster Children's Hospital

OTHER

collaborator

Stollery Children's Hospital

OTHER

collaborator

Children's Hospital of Eastern Ontario

OTHER

collaborator

St. Justine's Hospital

OTHER

collaborator

The Hospital for Sick Children

OTHER

lead

Suzanne Schuh

OTHER